Rakovina Therapeutics Executive Chairman Jeff Bacha and President and Chief Scientific Officer Mads Daugaard joined Steve Darling from Proactive to share more about the company that uses technology to target critical DNA damage repair pathway mutations that are the hallmarks of many cancers. Bacha telling Proactive more about the products they have in development including kt-3000 which is in the preclinical stage. Daugaard also share with Proactive more about the science and the types of Cancer they are focussing on.
Rakovina Therapeutics looking to use its technology to help patients battling cancer
